Parallel studies on the lipid shell functionalization with anti-human EpCAM or EGFR antibodies demonstrated different preferential binding abilities to several breast tumor cell lines with distinct marker expression profiles, and culminated in the production of multi-targeted anti-human EpCAM/EGFR MBs recognizing all cell lines with over 95% efficiency [102]. This evidence concerns the gene EPCAM and breast neoplasm.